INDIANAPOLIS (AP) A dime-size nanochip developed by a world-renowned researcher who recently relocated to Indianapolis could help transform the practice of medicine. It could also turn Indianapolis into a manufacturing and research hub for radically new disease and trauma treatment techniques.
It all began in August 2018, when Chandan Sen, one of the worlds leading experts in the nascent field of regenerative medicine, moved his lab from Ohio State University to the Indiana University School of Medicine. He brought along a team of about 30 researchers and $10 million in research grants, and now serves, among a myriad of other positions, as director of the newly formed Indiana Center for Regenerative Medicine and Engineering, to which IU pledged $20 million over its first five years.
IU recruited Sen away from Ohio State in part because of its desire not just to promote academic research in his field but also to help develop practical, commercial products and uses for his breakthroughs.
A scientist prefers to be in the lab and keep on making more discoveries, said Sen, 53.
But I thought that, unless we participate in the workforce development process and the commercialization process, I dont think that the businesspeople would be ready to do it all by themselves. Because its such a nascent field.
Its definitely new and its potential sounds like the stuff of science fiction.
Regenerative medicine, as its name hints, seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
For instance, instead of giving a diabetic a lifetimes worth of insulin injections, some of his skin cells could be altered to produce insulin, curing him. Such techniques might also be used for everything from creating lab-grown replacement organs to, someday, regenerating severed limbs.
Regenerative medicine offers a form of medicine that is neither a pill nor a device, Sen said.
It is a completely new platform, where you dont necessarily depend on any given drug, but are instead modifying bodily functions.
Sen and his teams signal contribution to the field is a technique theyve dubbed tissue nanotransfection, or TNT. Put simply, it uses a nanotechnology-based chip infused with a special biological cargo that, when applied to the skin and given a brief electrical charge, can convert run-of-the-mill skin cells into other cell types. Potentially, the technique could be used for everything from regrowing blood vessels in burn-damaged tissue to creating insulin-secreting cells that could cure diabetics.
Obviously, such applications are still down the road a ways. But the technology is far enough along that some products are already making it to market and investors, entrepreneurs and established companies are sniffing around for opportunities. According to the Alliance for Regenerative Medicine, more than 1,000 clinical trials worldwide are using regenerative medicine technologies.
Thousands of patients are already benefiting from early commercial products, and we expect that number will grow exponentially over the next few years, said Janet Lambert, the alliances CEO.
Lambert predicts that the number of approved gene therapies will double in the next one to two years. Last year, the U.S. Food and Drug Administration predicted it would be approving 10 to 20 cell and gene therapies each year by 2025.
These new techniques could do more than just revolutionize medicine. They could also upend the medical industry as we know it. And the IU School of Medicine and Indianapolis could lead the way.
There are really only two or three places in the country that did the kind of comprehensive work that Dr. Sens group was doing, said Anantha Shekhar, executive associate dean for research at IU School of Medicine. And they were doing it from the lab all the way to the clinic, where they were already applying those technologies in patients.
So it was very attractive to think of starting with a bang bringing a comprehensive group here and creating a new center.
Instead of merely treating chronic conditions, regenerative medicine could end them, once and for all.
For instance, consider a car with an oil leak. The traditional medical approach might be to live with the chronic condition by pouring in a fresh quart of oil every few days. The regenerative medicine approach would fix the leak. Its good for the car, good for the cars owner but not necessarily good for the guy who was selling all those quarts of oil.
Which is why these new techniques, if they catch on, could cause turmoil in the medical industry.
Because regenerative medicine has the potential to durably treat the underlying cause of disease, rather than merely ameliorating the symptoms, this technology has the potential of being extremely disruptive to the current practice of medicine, Lambert said.
This has the potential to be hugely disruptive, Sen added, because so much of medicine today relies on huge industrial infrastructures to manage, not cure, chronic diseases and disabilities.
If such disruption comes to pass, the leaders of 16 Tech, a 50-acre innovation district northwest of downtown that aspires to house dozens of medical-related startups and established firms, would love to be its epicenter.
The Center for Regenerative Medicine will be one of the tenants of 16 Techs first building, a $30 million, 120,000-square-foot research and office building scheduled to open in June.
Regenerative medicine is probably one of the next major waves of medical innovation in the world, 16 Tech CEO Bob Coy said. To have him here doing this work gives Indianapolis and Indiana an opportunity to develop an industrial cluster in regenerative medicine.
Coy believes the most momentous early step on that road was the recent establishment by Sen of masters and doctoral programs in regenerative medicine at the IU School of Medicine. Its the first degree of its type in the country, earning IU and Indianapolis the enviable status of first mover.
I think, for example, of (Pittsburghs) Carnegie Mellon University, which, back in the late 1960s, created the first college of computer science in the country, Coy said. And now you know Carnegie Mellons reputation in computer science.
What isnt in place yet is a state or city program to promote development of a regenerative medicine hub.
We need to start doing that, Coy said. That means putting a lot of the infrastructure in place to support startups that are based on this technology, as well as recruiting companies that want to collaborate with Dr. Sen.
In spite of the lack of a coherent recruitment program, Coys phone has started to ring, thanks largely to Sens presence.
There have been a few meetings Ive had with people who already have relationships with him, who, when they come to town, have reached out to meet and talk about what were doing at 16 Tech, he said.
One of the first 16 Tech startups with designs on the regenerative medicine niche is Sexton Biotechnologies.
The company was groomed by Cook Regentec, a division of Bloomington-based Cook Group charged with incubating and accelerating technologies for regenerative medicine and the related field of cell gene therapy.
Any products that show promise are either folded into the company, turned into their own divisions or, as in Sextons case, spun off as an independent entity with Cook retaining a financial stake.
Its a measure of the newness of this field that Sextons 17 employees arent working on new medicines, but rather marketing basic tools needed to conduct research. The companys offerings include a vial for storing cell and gene products in liquid nitrogen, and a cell culture growth medium.
Theres a ready market for such tailor-made gear, because, for years, researchers in the regenerative medicine field had to make do with jury-rigged equipment.
What most of those companies did was repurpose things like tools from the blood banking industry, or tools from bio pharma, said Sean Werner, Sextons president.
So thats why a lot of newer companies are starting to build tools explicitly for the industry, as opposed to everybody just having to cobble together stuff that was already out there.
Werner said investors recognize the momentous opportunity in regenerative medicine and are flocking to the field.
Its not something you have to explain, he said. Companies and VC groups are trying to get a piece of it.
What has investors and medical researchers charged up is the almost unlimited range of potential applications, from healing burns to, perhaps someday, regenerating limbs.
I think it would be a huge revolution if were able to, for example, regenerate insulin-secreting cells in children who have become juvenile diabetics or have for whatever reason lost their pancreas, Shekhar said. Those are the kinds of things that will start to change the way we see certain diseases.
Lambert predicted that, as the science advances, so will the business case.
While early programs focused primarily on rare genetic diseases and blood cancers, were already seeing the field expand into more common age-related neurological disorders, such as Parkinsons and Alzheimers, she said.
I expect this trend to continue in the coming years, greatly increasing the number of patients poised to benefit from these therapies.
Werner said regenerative medicine also is seeking advancements in manufacturing technologies that will lower the cost of product development.
It all adds up to a huge opportunity the state is well-positioned to seize, Werner believes.
Indiana is a perfect place for this kind of thing to really ramp up, he said. Theres no reason we cant lead the field.
Source: Indianapolis Business Journal
See original here:
IU team pursues breathtaking regenerative medicine advances - The Advocate
- Gene therapy innovations: Sarepta and Codiak partner on exosomes - Pharmaceutical Technology - July 13th, 2020
- DNA research aims to take 'trial and error' out of depression medication treatment - ABC News - July 13th, 2020
- The Wilderness of Rare Genetic Diseases and the Parents Navigating It - The New York Times - July 13th, 2020
- Physicians, Patients Need to Know Limits of DNA Privacy Law - Medscape - July 13th, 2020
- COVID-19 Impact on Regenerative Medicine Market: Outlook, Growth, Key Driving Players and Industry Analysis Report 2026 - Cole of Duty - July 13th, 2020
- African American, European Ancestry Men Benefit from Same Targeted Prostate Cancer Therapies - Clinical OMICs News - July 13th, 2020
- MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart - BioSpace - July 13th, 2020
- Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Lumasiran - BioSpace - July 13th, 2020
- Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies - UCSF News Services - July 13th, 2020
- Gene Editing Market Poised to Expand at a Robust Pace Over 2025 - 3rd Watch News - July 13th, 2020
- Uncovering the Unknowns to COVID-19 Testing | Center for Applied Genomics and Precision Medicine - Duke Today - July 13th, 2020
- Genetic Engineering Market Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2025 - Cole of Duty - July 13th, 2020
- NIH researchers reframe dog-to-human aging comparisons - National Institutes of Health - July 13th, 2020
- Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com - July 13th, 2020
- COVID-19: The lessons learned to date - Cosmos - July 13th, 2020
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of... - July 13th, 2020
- DNA Read, Write And Edit Market Sales Volume, Status, Growth, Opportunities and World the COVID-19 - 3rd Watch News - July 13th, 2020
- Jacobs School researchers collecting COVID-19 data - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - July 13th, 2020
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Duke researchers help discover new strain of coronavirus that spreads faster because of gene mutation - WGHP FOX 8 Greensboro - July 6th, 2020
- Phenotype and Molecular Detection of Clarithromycin and Levofloxacin R | IDR - Dove Medical Press - July 6th, 2020
- EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer - Business Wire - July 6th, 2020
- Matteo Adinolfi obituary | From the Guardian - The Guardian - July 6th, 2020
- Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2... - July 6th, 2020
- Bing and Ol' Medicine Hat - Todayville.com - July 6th, 2020
- Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se... - July 4th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 4th, 2020
- IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News - July 4th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 4th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - GlobeNewswire - July 4th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 4th, 2020
- Eliminating the Long, Cumbersome and Costly Diagnosis of Genetic Diseases - HIT Consultant - July 4th, 2020
- Rare Disease Diagnostics Industry Anticipated to Reach $26.7 Billion by 2024 - Market Shares by Disease Class, Indication, Analysis Platform, Analysis... - July 4th, 2020
- 28 cool health things that started with a Canadian - Regina Leader-Post - July 4th, 2020
- Pools in the Mexican desert are a window into Earth's early life - Science Magazine - July 4th, 2020
- Personalized Cancer Drugs Market Expected to Witness a Sustainable Growth over 2025 - 3rd Watch News - July 4th, 2020
- Genetic Medicine will be the Solution to COVID-19, and Ligandal is Leading the way - PR Web - June 20th, 2020
- Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta's ImmTOR Immune Tolerance Platform in... - June 20th, 2020
- Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End - June 20th, 2020
- FDA officials update on orphan drugs, gene therapies at DIA - Regulatory Focus - June 20th, 2020
- Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - PRNewswire - June 20th, 2020
- Pfizer and Sangamo report positive data from hemophilia A therapy trial - Clinical Trials Arena - June 20th, 2020
- Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty - June 20th, 2020
- UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - UCLA Newsroom - June 20th, 2020
- 15 Biotech Companies In Houston To Know - Built In - June 20th, 2020
- Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome - BioSpace - June 20th, 2020
- Global Precision Medicine Market Growth From 2019 to 2025- Market Report, Insights Analysis And Opportunities - Cole of Duty - June 20th, 2020
- Obesity in mice prevented by disabling gene - Medical News Today - May 24th, 2020
- COVID-19 study looks at genetics of healthy people who develop severe illness - Washington University School of Medicine in St. Louis - May 24th, 2020
- UBC scientist identifies a gene that controls thinness - UBC Faculty of Medicine - UBC Faculty of Medicine - May 24th, 2020
- IU team pursuing breathtaking advancements in regenerative medicine - The Republic - May 24th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - UAB News - May 24th, 2020
- COVID-19-Related Genes Have Higher Expression in Certain Patients With Asthma - Pulmonology Advisor - May 24th, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 24th, 2020
- Here's Why Editas Could Beat Intellia to a CRISPR Therapy - Motley Fool - May 24th, 2020
- FDA Approves Genentech's Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer - Business Wire - May 24th, 2020
- Doctors race to understand rare inflammatory condition associated with coronavirus in young people - Science Magazine - May 24th, 2020
- Retinoic acid synthesis by ALDH1A proteins is dispensable for meiosis initiation in the mouse fetal ovary - Science Advances - May 24th, 2020
- COVID-19 UPDATE: Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc,... - May 24th, 2020
- A Coronavirus Vaccine Candidate In Six Days? This Company Is Fast-Tracking Vaccine Development With The First Fully Automated Gene Synthesis Platform... - May 24th, 2020
- Precision medicine guides choice of better drug therapy in severe heart disease - Science Codex - May 17th, 2020
- Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Robert W. Baird - MarketBeat - May 17th, 2020
- Gene Editing Technologies in Diagnostic Platforms Market is expected to grow at a CAGR of 14.4% during the forecast period due to the rise in research... - May 17th, 2020
- Akouos to Present Data from Inner Ear Gene Therapy Platform at 23rd ASGCT Annual Meeting - Business Wire - May 14th, 2020
- Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases - GlobeNewswire - May 14th, 2020
- Gene therapy in mice builds muscle, reduces fat Washington University School of Medicine in St. Louis - Washington University School of Medicine in... - May 14th, 2020
- New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European... - May 14th, 2020
- Gene therapy drug for infants priced at 170 million yen : The Asahi Shimbun - Asahi Shimbun - May 14th, 2020
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the... - May 14th, 2020
- Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital... - May 14th, 2020
- bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual... - May 14th, 2020
- Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive... - May 14th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 14th, 2020
- Tech optimization: Unlocking the promise of precision medicine - Healthcare IT News - May 14th, 2020
- FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer - Cancer Health Treatment News - May 14th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 14th, 2020
- INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12... - May 14th, 2020
- 21-Gene Recurrence Scores of 26 or Higher Can Help Determine If Chemotherapy Will Be Effective - MedicalResearch.com - May 14th, 2020
- Obesity prevented in mice treated with gene-disabling nanoparticles - Washington University School of Medicine in St. Louis - May 1st, 2020
- Optics makes amazing things possible in biological research and medicineand Optikos makes it happen - Mass Device - May 1st, 2020